GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotest AG (OTCPK:BIESF) » Definitions » Cyclically Adjusted PS Ratio

Biotest AG (Biotest AG) Cyclically Adjusted PS Ratio : 2.86 (As of Jun. 08, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Biotest AG Cyclically Adjusted PS Ratio?

As of today (2024-06-08), Biotest AG's current share price is $30.48. Biotest AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $10.64. Biotest AG's Cyclically Adjusted PS Ratio for today is 2.86.

The historical rank and industry rank for Biotest AG's Cyclically Adjusted PS Ratio or its related term are showing as below:

BIESF' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.44   Med: 2.39   Max: 3.42
Current: 2.8

During the past years, Biotest AG's highest Cyclically Adjusted PS Ratio was 3.42. The lowest was 1.44. And the median was 2.39.

BIESF's Cyclically Adjusted PS Ratio is ranked better than
66.27% of 504 companies
in the Biotechnology industry
Industry Median: 5.47 vs BIESF: 2.80

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Biotest AG's adjusted revenue per share data for the three months ended in Mar. 2024 was $5.868. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $10.64 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Biotest AG Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Biotest AG's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotest AG Cyclically Adjusted PS Ratio Chart

Biotest AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.54 2.33 3.29 3.09 2.94

Biotest AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.01 3.00 2.95 2.94 2.87

Competitive Comparison of Biotest AG's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Biotest AG's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotest AG's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biotest AG's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Biotest AG's Cyclically Adjusted PS Ratio falls into.



Biotest AG Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Biotest AG's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=30.48/10.64
=2.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biotest AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Biotest AG's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=5.868/125.0381*125.0381
=5.868

Current CPI (Mar. 2024) = 125.0381.

Biotest AG Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 4.893 99.543 6.146
201409 4.669 99.823 5.848
201412 5.363 99.543 6.737
201503 4.039 99.717 5.065
201506 4.074 100.417 5.073
201509 3.696 100.417 4.602
201512 3.213 99.717 4.029
201603 4.133 100.017 5.167
201606 3.839 100.717 4.766
201609 3.740 101.017 4.629
201612 -0.155 101.217 -0.191
201703 1.785 101.417 2.201
201706 2.666 102.117 3.264
201709 3.023 102.717 3.680
201712 3.287 102.617 4.005
201803 2.693 102.917 3.272
201806 3.328 104.017 4.001
201809 2.644 104.718 3.157
201812 3.183 104.217 3.819
201903 2.919 104.217 3.502
201906 2.907 105.718 3.438
201909 2.916 106.018 3.439
201912 2.786 105.818 3.292
202003 2.799 105.718 3.311
202006 4.259 106.618 4.995
202009 3.249 105.818 3.839
202012 4.283 105.518 5.075
202103 3.749 107.518 4.360
202106 4.454 108.486 5.134
202109 3.440 109.435 3.930
202112 3.881 110.384 4.396
202203 3.386 113.968 3.715
202206 3.771 115.760 4.073
202209 2.759 118.818 2.903
202212 4.077 119.345 4.271
202303 3.260 122.402 3.330
202306 4.241 123.140 4.306
202309 6.818 124.195 6.864
202312 5.079 123.773 5.131
202403 5.868 125.038 5.868

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biotest AG  (OTCPK:BIESF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Biotest AG Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Biotest AG's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotest AG (Biotest AG) Business Description

Industry
Traded in Other Exchanges
Address
Landsteinerstrasse 5, Dreieich, DEU, 63303
Biotest AG is a supplier of biological medicines. The company produces its products from human blood plasma or manufactured by using biotechnology methods. It is engaged in the area of hematology, clinical immunology, and intensive care medicine. The operating business segments are Therapy, Plasma and Services, and Other segments. It generates maximum revenue from the Therapy segment. Geographically, it derives a majority of revenue from Central Europe and also has a presence in other countries.

Biotest AG (Biotest AG) Headlines

From GuruFocus

Nine Months 2019 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q4 2021 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Full Year 2019 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q3 2021 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q4 2020 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Nine Months 2020 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q3 2022 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q4 2022 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024